GlassScriptPhysician profile
Nirmala Kania
NPI 1831118009
$9,223.82
in general payments reported to CMS, 2019-2025
48 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,798 · 2020: $1,293 · 2021: $1,550 · 2022: $2,009 · 2023: $1,632 · 2024: $942.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,374 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,374.39 |
| Education | $199.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $921.19 | 2019-2024 | Opdivo |
| Pfizer INC. | $786.63 | 2019-2024 | |
| Janssen Biotech, INC. | $780.74 | 2019-2024 | Darzalex, Imbruvica, Tecvayli |
| Merck Sharp & Dohme LLC | $749.67 | 2019-2024 | Keytruda, Lynparza |
| Incyte Corporation | $705.27 | 2019-2024 | Jakafi |
| Amgen INC. | $595.97 | 2019-2024 | Nplate, Vectibix, Xgeva |
| Astrazeneca Pharmaceuticals LP | $419.83 | 2021-2024 | Tagrisso, Imfinzi, Enhertu |
| Bayer Healthcare Pharmaceuticals INC. | $414.10 | 2019-2024 | |
| Celgene Corporation | $386.66 | 2019-2023 | Pomalyst, Reblozyl |
| Alexion Pharmaceuticals, INC. | $347.66 | 2019-2024 | Ultomiris |
| Astellas Pharma US INC | $337.51 | 2019-2023 | Padcev |
| Glaxosmithkline, LLC. | $266.72 | 2020-2024 | Jemperli, Zejula |
| Novartis Pharmaceuticals Corporation | $253.42 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $220.30 | 2021-2024 | Ninlaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $207.46 | 2020-2024 | Jardiance |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nirmala Kania listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.